Meg Mains

May is GBS|CIDP Awareness Month

Building, Growing, and Expanding our community like never before! This awareness month we celebrate the expansion and inclusivity of our worldwide community! As our global network grows wider, our community…

Read More about May is GBS|CIDP Awareness Month

TAKEDA receives positive CHMP opinion for HYQVIA® as maintenance therapy in patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

TAKEDA receives positive CHMP opinion for HYQVIA® as maintenance therapy in patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use…

Read More about TAKEDA receives positive CHMP opinion for HYQVIA® as maintenance therapy in patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

SoHo Regulation in Trilogue Negotiation

On 12 September 2023, the European Parliament adopted the report on new rules governing the use of so-called substances of human origin (SoHO) intended for human application.  The Council still needs to…

Read More about SoHo Regulation in Trilogue Negotiation

2024 Research Grant Opportunities

As part of the GBS|CIDP Foundation International’s mission to provide education and support research, we offer research grants to qualified applicants. Through the generosity of these many individual contributors, to…

Read More about 2024 Research Grant Opportunities

2023 Virtual Summit

2023 Virtual Summit, Life After Diagnosis Back by popular demand, our 2023 Virtual Summit will feature a wide range of educational panels and presentations, as recorded at the 2022 Ponte Vedras, FL Patient Symposium &…

Read More about 2023 Virtual Summit